Humacyte Inc
$ 1.30
0.78%
04 Dec - close price
- Market Cap 243,453,000 USD
- Current Price $ 1.30
- High / Low $ 1.33 / 1.26
- Stock P/E N/A
- Book Value -0.03
- EPS -0.27
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.63 %
- ROE -2.50 %
- 52 Week High 6.77
- 52 Week Low 1.09
About
None
Analyst Target Price
$7.86
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-07 | 2025-08-11 | 2025-05-08 | 2025-03-20 | 2024-11-07 | 2024-08-13 | 2024-05-10 | 2024-03-22 | 2023-11-09 | 2023-08-14 | 2023-05-12 | 2023-03-24 |
| Reported EPS | -0.1415 | -0.24 | -0.0804 | -0.2091 | -0.33 | -0.48 | -0.29 | -0.24 | -0.25 | -0.22 | -0.36 | -0.04 |
| Estimated EPS | -0.1591 | -0.16 | -0.22 | -0.255 | -0.25 | -0.24 | -0.22 | -0.24 | -0.25 | -0.22 | -0.21 | -0.23 |
| Surprise | 0.0176 | -0.08 | 0.1396 | 0.0459 | -0.08 | -0.24 | -0.07 | 0 | 0 | 0 | -0.15 | 0.19 |
| Surprise Percentage | 11.0622% | -50% | 63.4545% | 18% | -32% | -100% | -31.8182% | 0% | 0% | 0% | -71.4286% | 82.6087% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: HUMA
2025-10-18 05:20:32
Humacyte, Inc. (NASDAQ:HUMA) has received a consensus target price of $8.38 from brokerages, with recent analyst ratings including a "buy" from D. Boral Capital with a $25.00 objective and BTIG Research with a lowered $6.00 objective. The article also details recent insider stock sales by director Brady W. Dougan and institutional investment activity, with hedge funds increasing and purchasing new positions in the company's stock. Humacyte is recognized for its work in developing bioengineered human tissues.
2025-10-18 02:40:01
Humacyte, Inc. (HUMA) closed up +1.18% in its latest trading session, outperforming the S&P 500. The company is set to report earnings with an estimated EPS growth of 48.48% year-over-year. Analysts have not changed their Zacks Consensus EPS estimate, maintaining a Zacks Rank #3 (Hold) for Humacyte, Inc.
2025-10-16 11:08:07
Humacyte (HUMA) has garnered attention due to promising long-term results from its humanitarian program in Ukraine, showing sustained vessel patency and limb salvage with no infections in trauma cases. Despite recent engineering milestones and a stock gain of 15.7% over the past month, its one-year return remains deeply negative (-69.5%). The company's high price-to-book ratio of 69.4x suggests investor expectations for future success, yet lingering risks like negative earnings and reliance on clinical milestones persist.
2025-10-15 21:58:34
Humacyte, Inc. has successfully secured $60 million through an oversubscribed registered direct offering to institutional investors, facilitating the advancement of its bioengineered human tissues. This funding follows the FDA approval of its acellular tissue engineered vessel (ATEV) for extremity vascular trauma in December 2024. The capital will support continued clinical development for applications like hemodialysis access and peripheral artery disease, as well as commercialization efforts for its approved product.
2025-10-15 07:23:19
Humacyte, Inc. (HUMA) shares increased by 1.7% to $1.79, outperforming the S&P 500's daily loss. The company has seen a 15.03% gain over the past month, surpassing both the Medical sector and the S&P 500, with analysts projecting a significant improvement in its upcoming earnings. Zacks maintains a #3 (Hold) rank for HUMA, noting positive estimate revisions and the strong performance of its industry within the Medical sector.
2025-10-15 00:30:25
Humacyte, Inc. (HUMA) saw its stock price increase by 1.7% to $1.79 while the broader market declined. The company has gained 15.03% over the past month, outperforming its sector and the S&P 500. Investors are anticipating its upcoming earnings report, with Zacks analysts projecting significant EPS growth and a "Hold" rating.
